2612-P: AI/ML-Driven Genetic Discovery through In Vivo Validation of Obesity Targets
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-2612-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von JONATHAN CHOY und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: Brown adipose tissue (BAT) plays a key role in non-shivering thermogenesis and is strongly implicated in obesity and metabolic disease, and may offer an alternative therapeutic strategy for treating obesity and its related comorbidities.
Methods
Starting from a BAT-ML (an in-house machine learning (ML)-derived BAT phenotype) GWAS, we investigated the relevance of these genetic signals in vitro using human adipocyte cell models and in vivo in HFD obese mice.
Results
At least 1 target identified through BAT-ML was found to reduce body weight and fat mass AND increased BAT/beige-like character in vivo.
Conclusion
Here, we present the first BAT-ML GWAS and prosecution of the genetic insights in adipocyte cell models through in vivo validation in support of targeting BAT for potentially treating obesity and its related comorbidities. Disclosure J. Choy: Employee; Current; insitro. Employee; Ended; Maze Therapeutics. Stock/Shareholder; Current; Maze Therapeutics, Merck & Co., Inc. D. Lloyd: None.
Zitieren
APA
CHOY, J., & LLOYD, D. (2026). 2612-P: AI/ML-Driven Genetic Discovery through In Vivo Validation of Obesity Targets. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2612-p
Vancouver
CHOY J, LLOYD D. 2612-P: AI/ML-Driven Genetic Discovery through In Vivo Validation of Obesity Targets. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2612-p
BibTeX
@article{CHOY2026,
author = {CHOY, JONATHAN and LLOYD, DAVID},
title = {2612-P: AI/ML-Driven Genetic Discovery through In Vivo Validation of Obesity Targets},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-2612-p}
}
EUVIMED